Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of AMG 691 in asthma (3 arms), sponsored by Amgen. Primary endpoint: Treatment-emergent Adverse Events at 11 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
AMG 691
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06637371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637371.